Two Second-Generation Trabecular Micro-bypass Stents to Treat Glaucoma Subjects on One Hypotensive Medication

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

57 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-03-31

Study Completion Date

2019-11-08

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study objective is to evaluate the intraocular pressure (IOP) lowering effect of two trabecular micro-bypass stents (iStent inject) in eyes of subjects with primary open-angle glaucoma on one topical hypotensive medication

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent)or Travoprost

NCT01443988

Open-angle Glaucoma

COMPLETED PHASE4

Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent Inject) or Travoprost

NCT01444040

Open-angle Glaucoma

COMPLETED PHASE4

Open-Angle Glaucoma Subjects With One Prior Trabeculectomy Treated Concurrently With One Suprachoroidal Stent and Two Trabecular Micro-bypass Stents

NCT01456390

Open-Angle Glaucoma

COMPLETED NA

Prospective Evaluation of Open-Angle Glaucoma Subjects on One Topical Hypotensive Medication Treated With Two iStents

NCT01252862

Subjects With Primary Open-angle Glaucoma (POAG)

COMPLETED PHASE4

Open-angle Glaucoma Subjects on One Ocular Hypotensive Medication Randomized to Treatment With Two Trabecular Micro-bypass Stents or Selective Laser Trabeculoplasty

NCT01444105

Open-angle Glaucoma

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study design is as follows:

Prospective

Subjects with medicated IOP \> 18 mmHg and ≤ 30 mmHg

Subjects on one topical ocular hypotensive medication prior to stent implantation

Implantation of two iStent devices (if IOP is \< 6 mmHg, at any point during the postoperative follow-up, medication will not be prescribed or will be discontinued)

IOP will be measured by two (2) observers to minimize bias; observer 1 will look through the slit lamp and turn the dial with readings being masked, and observer 2 will document the IOP

Diurnal IOP measurements

Follow-up through 60 months postoperative (but could be up to 61 months if subject needs to undergo terminal washout)

Descriptive statistics will be tabulated

Medical therapy considered necessary for the subject's welfare can be implemented at any time during the study at the investigator's discretion

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Open Angle Glaucoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Two micro-bypass stents (iStent inject)

Standalone implantation of two trabecular micro-bypass stents (iStent inject)

Group Type OTHER

Two trabecular micro-bypass stents (iStent inject)

Intervention Type DEVICE

Standalone implantation of two trabecular micro-bypass stents (iStent inject)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Two trabecular micro-bypass stents (iStent inject)

Standalone implantation of two trabecular micro-bypass stents (iStent inject)

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Phakic patients or pseudophakic patients with posterior chamber intraocular lenses (PC-IOLs).
* Primary open-angle glaucoma (including pigmentary or pseudoexfoliative).
* Cup-to-disc ratio ≤ 0.9.
* Visual field defects, or nerve abnormality characteristic of glaucoma.
* One topical hypotensive medication at time of screening exam.
* Intraocular pressure (IOP) \> 18 mmHg and ≤ 30 mmHg (medicated) at screening exam.
* Study eye BCVA 20/100 or better.
* Normal angle anatomy as determined by gonioscopy.
* Absence of peripheral anterior synechia (PAS), rubeosis or other angle abnormalities that could impair proper placement of stent.

* Subject has completed appropriate medication washout.
* Mean IOP \> 22 mmHg and ≤ 38 mmHg after anti-glaucoma medication washout period.

Exclusion Criteria

* Aphakic patients or pseudophakic patients with anterior chamber IOLs (AC-IOLs).
* Prior stent implantations (study eye).
* Traumatic, uveitic, neovascular, or angle-closure glaucoma; or glaucoma associated with vascular disorders.
* Functionally significant visual field loss, including severe nerve fiber bundle defects such as Bjerrum scotoma.
* Prior incisional glaucoma surgery.
* Prior SLT within 90 days prior to screening.
* Prior ALT.
* Iridectomy or laser iridotomy.
* Ineligibility for ocular hypotensive medication washout period as determined by the investigator such as: visual field status would be placed at risk by washout period, or unmedicated IOP after washout period would be expected to exceed upper limit of ≥ 38 mmHg.
* Any active corneal inflammation or edema (e.g., keratitis, keratoconjunctivitis, keratouveitis).
* Clinically significant corneal dystrophy (e.g., bullous keratopathy, Fuch's dystrophy); any guttata.
* Corneal surgery (prior or anticipated) of any type (including LASIK, LASEK, PRK, etc.) that may interfere with IOP measurement reliability.
* Corneal opacities or disorders that would inhibit visualization of the nasal angle.
* Congenital or traumatic cataract.
* Retinal or optic nerve disorders, either degenerative or evolutive, that are not associated with the existing glaucoma condition.
* Elevated episcleral venous pressure such as associated with: active thyroid orbitopathy, cavernous sinus fistula, Sturge-Weber syndrome, orbital tumors, orbital congestive disease.
* Clinically significant sequelae from trauma (e.g., chemical burns, blunt trauma, etc.).
* Chronic ocular inflammatory disease or presence of active ocular inflammation (e.g., uveitis, iritis, iridocyclitis, retinitis).
* Pregnant or nursing women.

* Subject did not complete medication washout.
* Mean IOP \< 22 mmHg or \> 38 mmHg after anti-glaucoma medication washout.
* Subject did not have a 3mmHg IOP increase over screening mean diurnal IOP.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No